

Hickman M, Dillon J, Elliott L, De Angelis D, Vickerman P, Foster G, Donnan PT, Eriksen A, Flowers P, Goldberg D, Hollingworth W, Ijaz S, Liddell D, Mandal S, Martin NK, Beer L, Drysdale K, Fraser H, Glass R, Graham L, Gunson R, Hamilton E, Harris H, Harris M, Harris R, Heinsbroek E, Hope V, Horwood J, Inglis S K, Innes H, Lane A, Meadows, J, Thorne B, McAuley A, Metcalfe C, Mighelsen S, Murray, A, Myring G, Palmateer N, Presanis A, Radley A, Ramsay M, Samartsidis P, Simmons R, Sinka K, Vojt, G, Ward Z, Whiteley D, Yeung, A, Hutchinson S

EPIToPe Overview

The primary aim of EPIToPe is to generate UK empirical evidence on the effectiveness of HCV 'Treatment as Prevention' in people who Inject drugs (PWID).

Theoretical mathematical modelling evidence suggests HCV treatment scale-up can prevent transmission and substantially reduce HCV prevalence and incidence among PWID.

In Tayside we have demonstrated successful scale-up of DAAs among PWID with testing and treatment in multiple community settings and observed substantial reduction in chronic HCV in the population.

A qualitative study interviewed service users and providers to identify facilitators and barriers to scaling-up HCV testing and treatment for PWID, resulting in a set of recommendations.



Available at: https://www.gcu.ac.uk/_data/assets/pdf_file/0019/38350/epitope_manual_recommndations_final_version_sep2021.pdf

We are finalising a model for our WS5 evaluation of HCV TasP, with the effect of intervention (DAAs) being the difference between:

observed outcome with DAAs scale-up and **counterfactual**: the outcome that we would observe if there were no scale-up from 2015.

We can also use this to estimate the probability that specific "elimination" targets have been met .

Hickman M, et al. *BMJ Open* 2019. PMID: 31551376 PMCID: PMC6773339 DOI: 10.1136/bmiopen-2019-029538



EPIToPe at INHSU 2022: where to find out more

PRESENTATION:

Real-world examples of success in achieving HCV elimination among people who inject drugs: Scotland

John Dillon, University of Dundee, UK

Thursday 20th October
Loch Lomond Auditorium: Session K
09:20am

PRESENTATION:

Evaluating the impact of direct-acting anti-viral therapy on Hepatitis C Viraemia among people who inject drugs

Pantelis Samartsidis,
University of Cambridge, UK

Thursday 20th October
Room Dochart: Session O
14:00pm

PRESENTATION:

Changing Trends in Hepatitis C Reinfection Rates Following the Scale-up of Direct-Acting Antivirals Among People Who Inject Drugs in Scotland

Norah Palmateer,
Glasgow Caledonian University, UK

Thursday 20th October
Room Dochart: Session O
14:15pm

PRESENTATION:

Changes in self-reported quality of life associated with successful DAA hepatitis C treatment in people who use drugs

Scott McDonald,
Glasgow Caledonian University, UK

Thursday 20th October
Loch Lomond Auditorium: Session K
10.15am

WORKSTREAM 3 POSTERS

1. Patient reported outcomes of recovery and quality of life post hepatitis C treatment.
2. Integrating hepatitis C testing and treatment into multiple community healthcare settings for those who inject drugs: Facilitators and Barriers.
3. Integrating hepatitis C testing and treatment into community healthcare settings for those who inject drugs: Formulating Recommendations

WORKSHOP:

Peer research in Hepatitis C Treatment for Those Who Inject Drugs

Lawrie Elliot and Gabriele Vojt
Glasgow Caledonian University, UK

Thursday 20 October 2022
11:15am – 12:15pm
Scottish Event Campus

POSTER PRESENTATIONS:

Higher incidence of HCV re-infection among treatment experienced people who inject drugs in Tayside, Scotland.

Christopher Byrne, University of Dundee, UK
Poster Tour 01: Wednesday 19th October 15.55pm

Overlapping adverse health outcomes among people who inject drugs in England, Wales and Northern Ireland, 2019-2020

Claire Edmundson, UK Health Security Agency, UK
Poster Tour 04 Friday 21st October 11.15am

For further information on any of the work EPIToPe is conducting, please contact:

[EPIToPe | Bristol Medical School: Population Health Sciences | University of Bristol](#)

Email: Beth.Thorne@bristol.ac.uk

This study is funded by the National Institute for Health Research (NIHR) Programme Grants for Applied Research programme (Grant Reference Number RP-PG-0616-20008). The views expressed are those of the author(s) and not necessarily those of the NIHR or the Department of Health and Social Care.

FUNDED BY